TMC
GLMD icon

Trellus Management Company’s Galmed Pharmaceuticals GLMD Stock Holding History

Trellus Management Company’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-93
Closed -$227K – 53
2018
Q3 		$227K Buy
+93
New +$218K 0.33% 55

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Trellus Management Company's GLMD Position: Q4 2018 in Review

Trellus Management Company sold out of Galmed Pharmaceuticals (GLMD) in Q4 2018, closing a stake of 93 shares — an estimated $227K sold.

Trellus Management Company first reported a position in GLMD in Q3 2018 and held it in 1 quarter. The position peaked at $227K in Q3 2018. 42 funds tracked by Wall St. Rank hold GLMD as of Q4 2018.

  • Trellus Management Company reported no remaining Galmed Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Trellus Management Company sold 93 Galmed Pharmaceuticals shares in Q4 2018, an estimated $227K.
  • Trellus Management Company first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Trellus Management Company's Galmed Pharmaceuticals position peaked at $227K in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2018.

Based on Trellus Management Company's 13F filing for Q4 2018, filed 4 Feb 2019.